# US 2020/0369719 A1 · Depletion of Light Chain Mispaired Antibody Variants By Hydrophobic Interaction Chromatography

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0369719 A1
- Document ID: US20200369719A1
- Status: Published application
- Kind: A1
- Application number: 16/955,776
- Filed: 2018-12-20
- Published: 2020-11-26
- Earliest claimed: 2017-12-22
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Thomas Von Hirschheydt; Petra Rueger; Birgit Weydanz; Hubert Hertenberger
- Web page: https://patentgrep.com/patent/US20200369719A1

## CPC

- C07K 1/20: Partition-, reverse-phase or hydrophobic interaction chromatography
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/065: {Purification, fragmentation}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/40: against enzymes
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/55: Fab or Fab'
- C07K 2317/66: comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods for separating multispecific CrossMab antibodies from light chain mispaired variants thereof in a solution comprising CrossMab bispecific antibodies and mispaired antibody variants thereof by hydrophobic interaction chromatography.

## Claims

### Claim 1

A method for separating a multispecific CrossMab antibody from a mispaired variant thereof by using a hydrophobic interaction chromatography (HIC) medium, the medium comprising a matrix of particles substituted with ligands,
(i) wherein said particles have an average size of 50 μm or less in diameter and said ligands are butyl groups;
(ii) wherein said particles have an average size of from 35 μm to 60 μm in diameter and said ligands are phenyl groups; or
(iii) wherein said particles have an average size of from 35 μm to 100 μm in diameter and said ligands are polypropylene glycol groups.

### Claim 2

A method for separating a multispecific CrossMab antibody from a mispaired variant thereof, comprising
subjecting a solution comprising said CrossMab antibody and said mispaired variant thereof to a hydrophobic interaction chromatography (HIC) step, thereby obtaining said CrossMab antibody depleted of said mispaired variant thereof,
wherein the chromatographic medium used in said HIC step comprises a matrix of particles substituted with ligands,
(i) wherein said particles have an average size of 50 μm or less in diameter, and said ligands are butyl groups;
(ii) wherein said particles have an average size of from 35 μm to 60 μm in diameter, and said ligands are phenyl groups; or
(iii) wherein said particles have an average size of from 35 μm to 100 μm in diameter, and said ligands are polypropylene glycol (PPG) groups.

### Claim at position 3

3-4. (canceled)

### Claim 5 (depends on 2)

The method for separating a multispecific CrossMab antibody according to claim 2, wherein at least one of the Fab regions of said antibody is a Fab region, in which the variable and/or constant domains of the heavy and light chain are exchanged and provided that not the same exchange is made in Fab regions of different binding specificity and provided that the same exchange is made in Fab regions having the same binding specificity.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the HIC medium is selected from the group consisting of Butyl Sepharose® HP, Capto Butyl ImpRes, Capto Phenyl ImpRes and Toyopearl® PPG-600M.

### Claim 7 (depends on 2)

The method according to claim 2, wherein said multispecific CrossMab antibody is a multispecific antibody comprising
(a) a first antigen binding region specifically binding to a first antigen, wherein the first antigen binding region comprises the light chain and heavy chain of an antibody specifically binding to a first antigen, and
(b) a second antigen binding region specifically binding to a second antigen, wherein the second antigen binding region comprises the light chain and heavy chain of an antibody specifically binding to a second antigen, wherein in the second antigen binding region
(i) the constant domains CL and CH1 are replaced by each other, and/or
(ii) the constant domains VL and VH are replaced by each other.

### Claim 8 (depends on 7)

The method according to claim 7, wherein said multispecific antibody is a bispecific bivalent antibody, a bispecific trivalent or a bispecific, tetravalent antibody.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the multispecific antibody is bivalent for the first antigen and bivalent for the second antigen.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the antibody comprises
(a) two of said first antigen binding regions; and
(b) two of said second antigen binding regions,
wherein each of said second antigen binding regions is fused via a peptide connector either at the C- or N-terminus of the heavy chain of one of said first antigen binding regions.

### Claim 11 (depends on 10)

The method according to claim 10, wherein
the antibody is an IgG antibody and the heavy chains of said first antigen binding regions comprise CH2 and CH3 domains, and wherein each of said second antigen binding regions is fused via a peptide connector to the C-terminus of the heavy chain of one of said first antigen binding regions.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the antibody comprises
a) two light chains and two heavy chains of an antibody, which specifically binds to a first antigen and comprises two Fab regions;
b) two additional Fab regions of an antibody which specifically binds to a second antigen, wherein said additional Fab regions are fused both via a peptide connector either at the C- or N-termini of the heavy chains of a); wherein in the Fab regions the following modifications are performed:
i) in both Fab regions of a), or in both Fab regions of b), the variable domains VL and VH are replaced by each other, and/or the constant domains CL and CH1 are replaced by each other,
ii) in both Fab regions of a) the variable domains VL and VH are replaced by each other, and the constant domains CL and CH1 are replaced by each other, and in both Fab regions of b) the variable domains VL and VH are replaced by each other, or the constant domains CL and CH1 are replaced by each other,
iii) in both Fab regions of a) the variable domains VL and VH are replaced by each other, or the constant domains CL and CH1 are replaced by each other, and in both Fab regions of b) the variable domains VL and VH are replaced by each other, and the constant domains CL and CH1 are replaced by each other,
iv) in both Fab regions of a) the variable domains VL and VH are replaced by each other, and in both Fab regions of b) the constant domains CL and CH1 are replaced by each other, or
v) in both Fab regions of a) the constant domains CL and CH1 are replaced by each other, and in both Fab regions of b) the variable domains VL and VH are replaced by each other.

### Claim 13 (depends on 2)

The method of according to claim 2, wherein the multispecific CrossMab antibody and said mispaired variant thereof are separately eluted from the HIC medium, thereby separating the multispecific CrossMab antibody from the mispaired variant thereof in the solution based on hydrophobicity.

### Claim 14 (depends on 2)

The method of according to claim 2, wherein the matrix is a polymeric matrix or an agarose-based matrix, preferably the matrix comprises between 4 and 6% agarose.

### Claim 15 (depends on 2)

The method according to claim 2, wherein the density of the substituted ligands is between 9 and 50 μmol per ml HIC medium.

### Claim 16 (depends on 2)

The method according to claim 2, wherein the HIC medium has a dynamic binding capacity of between 19 and 39 mg of bovine serum albumin per mL medium.

### Claim 17 (depends on 2)

The method according to claim 2, wherein said method further comprises one or more further purification step(s) prior and/or after the HIC step.

### Claim 18 (depends on 2)

The method according to claim 2, wherein the mispaired variant thereof is a variant of said multispecific CrossMab antibody, wherein one or more light chains are paired with a non-complementary heavy chain.
